Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.
- Resource Type
- Article
- Source
- Arthritis Research & Therapy; 4/22/2016, Vol. 18, p1-7, 7p
- Subject
- Language
- ISSN
- 14786354